

CURRICULUM VITAE ABREVIADO

Antonio Lopez-Beltran M.D, Ph.D.

CV Fecha: Marzo, 2019

INFORMATION PERSONAL

Nombre: Antonio Lopez-Beltran

Dirección: C/Bellavista Las Jaras B 20, Córdoba

Telefono: 629581494

E-mail: emllobea@gmail.com o emllobea@uco.es

Ciudadanía: España (European Union)

POSICIONES

-Professor Titular de Anatomia Pathologica, Facultad de Medicina, Córdoba, 1986-2007

-Medico Anatomopatologo: Hospital Reina Sofia, Córdoba, 1983-2007

POSITION ACTUAL

-Catedrático de Anatomia Patologica, Universidad de Córdoba, Facultad de Medicina, Córdoba, 2007-actualidad, Córdoba, España

FORMACION

-Licenciado en Medicina y Cirugia, Universidad de Sevilla, 1973-1979

-Residencia de Anatomia Patologica, Hospital Universitario de Sevilla, 1979-1982

-Doctor en Medicina y Cirugía, Universidad de Cordoba, 1981-1984

PROFESOR VISITANTE

- Anatomic Pathology, University College Hospital, London, UK, 1986 (6 months)
- Oncopathology, Roswell Park Cancer Institute, Buffalo, NY, 1987-1989 (2 years)
- Uropathology/Surgical Pathology, Mayo Clinic, Rochester, MN, 1995 (6 months)
- Molecular Oncology, Heidelberg University, Heidelberg, 2006 (1 month)

PERTENENCIA A ORGANIZACIONES PROFESIONALES Y CIENTIFICAS

- Member of the USCAP and the European Society of Pathology (ESP)
- Founding Member of the International Society of Uropathology-ISUP
- Chairman, European Working Group on Urologic Pathology (ESP)
- Chairman, European Section of Uropathology (ESUP) (full section member of the European Association of Urology-EAU)

CLASIFICACION DE LA ORGANIZACIÓN MUNDIAL DE LA SALUD DE LOS TUMORES UROLOGICOS

- Member of the Experts Panel on Urologic Tumors that developed the 2004 WHO classification of Urologic Tumors. Book publication 2004.
- Member of the Experts Panel on Urologic Tumors that will developed the 2015 WHO classification of Urologic Tumors (expert meeting on march 2015). Book publicación 2016.

PUBLICACIONES-ARTICULOS

PubMed: 546 entradas (Lopez-Beltran A; Beltran AL) (Acceso 18 de Marzo 2019)

“H”index = 61 (Marzo 2019, Google Academic)

10 Publicaciones más citadas

1. Epstein J I; M B Amin; V R Reuter; F K Mostofi; F Algaba; Allsbrook; A G Ayala; M J Becich; A **Lopez Beltran**; L Boccon-Gibod; D G Bostwick and the bladder consensus conference committee. A consensus classification of the urothelial lesions of the urinary bladder. American Journal of Surgical Pathology 22:1435-1448, 1998 (**Citaciones 897**)
2. **Lopez-Beltran A**, M Scarpelli, R Montironi, Z Kirkali. WHO classification of the renal tumors of the adults – European Urology, Volume 49, Issue 5, May 2006, Pages 798–805 (**Citaciones 720**)
3. Bostwick D G; Pacelli A; **Lopez Beltran, Antonio**. Molecular biology of prostatic intraepithelial neoplasia. Prostate 29:117-134, 1996 (**Citaciones 262**)
4. **Lopez Beltran, Antonio**; A Pacelli; H J Rothenberg; P C Wollan; H Zincke; M L Blute; D G Bostwick. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. Journal of Urology 159:1497-1503, 1998 (**Citaciones 238**)
5. Cheng L, XJ Yang, A **lopez-beltran**, et al Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients - Cancer, 2004, 101 :957-962. (**Citaciones 273**)
6. A **Lopez-Beltran**, S Suzigan, R Montironi et al. Multilocular cystic renal cell carcinoma: a report of 45 cases of a kidney tumor of low malignant potential ... - American journal of Clinical Pathology 125:217-222, 2006 (**Citaciones 167**)
7. L Cheng, M-T Sung, P Cossu-Rocca, TD Jones, GT MacLennan, J De Jong, A **Lopez-Beltran**, R Montironi, LHJ Looijenga. OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. The Journal of Pathology Volume 211, Issue 1, pages 1–9, January 2007 (**citaciones 215**)
8. A **Lopez-Beltran**, G Sauter, T Gasser, A Hartmann, BJ et al - World Health Organization classification of tumors, 2004. Infiltrating urothelial carcinoma (**Citaciones 220**)
9. A **Lopez-Beltran**, R Montironi - Non-invasive urothelial neoplasms: according to the most recent WHO classification. European urology, Volume 46, Issue 2, August 2004, Pages 170–176. (**Citaciones 190**)

10. **A Lopez-Beltran, L Cheng.** Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications- Human pathology, 2006 Nov;37(11):1371-88. (**Citaciones 181**)

10 Publicaciones Recientes área Medicina/Oncología Predictiva

1. Cheng L, **Lopez-Beltran A**, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018 Jan;31(1):24-38. doi: 10.1038/modpathol.2017.104.
2. Mann SA, **Lopez-Beltran A**, Massari F, Pili R, Fiorentino M, Koch MO, Kaimakliotis HZ, Wang L, Scarpelli M, Ciccarese C, Moch H, Montironi R, Cheng L. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. Curr Drug Metab. 2017 Oct 16;18(8):700-711. doi: 10.2174/1389200218666170518162500.
3. **Lopez-Beltran A**, Cheng L, Montorsi F, Scarpelli M, Raspollini MR, Montironi R. Concomitant bladder cancer and prostate cancer: challenges and controversies. Nat Rev Urol. 2017 Oct;14(10):620-629. doi: 10.1038/nrurol.2017.124.
4. Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, **Lopez-Beltran A**, Cheng L, Montironi R. Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Rev Mol Diagn. 2017 Aug;17(8):781-789. doi: 10.1080/14737159.2017.1341314.
5. Cheng L, Montironi R, **Lopez-Beltran A**. TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. Eur Urol. 2017 Mar;71(3):497-498. doi: 10.1016/j.eururo.2016.12.008.
6. **Lopez-Beltran A**, Cheng L, Raspollini MR, Montironi R. SMARCB1/INI1 Genetic Alterations in Renal Medullary Carcinomas. Eur Urol. 2016 Jun;69(6):1062-4. doi: 10.1016/j.eururo.2016.01.002.
7. Santoni M, Scarpelli M, Mazzucchelli R, **Lopez-Beltran A**, Cheng L, Epstein JI, Cascinu S, Briganti A, Catto JW, Montorsi F, Montironi R. Current Histopathologic

and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. Eur Urol. 2016 Feb;69(2):186-90. doi: 10.1016/j.eururo.2015.05.041

8. Fisher KW, **Lopez-Beltran A**, Montironi R, Cheng L. Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. Future Oncol. (2015) 11(19), 2711–2719
9. **Lopez-Beltran A**, Santoni M, Massari F, Ciccicarese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C, Montironi R. Bladder cancer: molecular determinants of personalized therapy. Curr Drug Targets. 2015;16(2):115-24.
10. Cheng L, Alexander RE, MacLennan GT, Cummings OW, Montironi R, **Lopez-Beltran A**, Cramer HM, Davidson DD, Zhang S. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 2012 Mar;25(3):347-69. doi: 10.1038/modpathol.2011.215.

Libros Recientes

1. Cheng L, **Lopez-Beltran A**, Bostwick DG. Bladder Pathology. Wiley-Blackwell, 2012
2. **Lopez-Beltran A**, Menendez CL, Montironi R, Cheng L. Rare Tumors and Tumor-Like Conditions in Urological Pathology. Springer, 2015
3. **Lopez-Beltran A**, Montironi R, Cheng L. Pathology of the Urinary Bladder. An Algorithmic Approach. Cambridge, 2016
4. **Lopez-Beltran A**, Cheng L, Raspollini MR, Montironi R. Pathology of the Prostate. An Algorithmic Approach. Cambridge, 2017
5. **Raspollini MR y Lopez-Beltran A**. Gynecologic and Urologic Pathology. Similarities, Differences, and Challenges. Cambridge 2019.